Evidence map›Paper›PMID 30699061›Full record

ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Linear Polyethylenimine-DNA Nanoconstruct for Corneal Gene Delivery.

Jason T Rodier, Ratnakar Tripathi, Michael K Fink, Ajay Sharma, Madhuri Korampally, Shubhra Gangopadhyay, Elizabeth A Giuliano, Prashant R Sinha, Rajiv R Mohan

Open access · greenAbstract read
In one paragraph

Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Corneal stromal repair and regeneration.Progress in retinal and eye research · 2022
    Review
  2. Effects of Regular/Dilute Proparacaine Anesthetic Eye Drops in Combination with Ophthalmic Antibiotics on Corneal Wound Healing.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Novel insights into gene therapy in the cornea.Experimental eye research · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jason T Rodier1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Ratnakar Tripathi1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Michael K Fink1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Ajay Sharma1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Madhuri Korampally1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Shubhra Gangopadhyay4 Department of Electrical and Computer Engineering, University of Missouri, Columbia, Missouri.
Elizabeth A Giuliano1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Prashant R Sinha1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
Rajiv R Mohan1 Research Divison, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri.
University of Missouri Health System · USHarry S. Truman Memorial Veterans' Hospital · USUniversity of Missouri · USVision Eye Institute · AU

Funding

Gene Therapy in the CorneaR01EY017294 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2007 to 2018
$4.3M
BLRD VA I01 BX000357BLRD VA IK6 BX005646NEI NIH HHS R01 EY017294
6 · The paper itself

Abstract

purposeThis study investigated the efficiency and potential toxicity of a linear 22-kDa polyethylenimine (PEI)-DNA nanoconstruct for delivering genes to corneal cells and the effects of PEI nitrogen-to-DNA phosphate (N:P) ratio on gene transfer efficiency in vitro and in vivo.

methodsA gel retardation assay, zeta potential measurement, bright-field microscopy, transfection with green fluorescent protein (GFP), immunofluorescence, and enzyme-linked immunosorbent assay (ELISA) were used to characterize the physicochemical and biological properties and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH), and reactive oxygen species (ROS) assay for cytotoxicity of the linear PEI-DNA nanoconstruct using in vitro cultured primary human corneal fibroblast and in vivo mouse models.

resultsOf the several evaluated N:P ratios, the highest gene transfection efficiency achieved without any notable cytotoxicity was observed at an N:P ratio of 30:1 (N:P 30). In vivo gene transfer studies revealed substantial GFP gene delivery into the corneas of mice 3 days after a single 5-min topical application without any significant adverse ocular effects. Slit-lamp biomicroscope ophthalmic examination of the mouse exposed to the linear PEI-DNA nanoconstruct showed no evidence of hyperemia (redness), corneal edema, ocular inflammation, or epiphora (excessive tearing).

conclusionsThe 22-kDa linear PEI-DNA nanoconstruct is an efficient and well-tolerated vector for corneal gene therapy in vitro and in vivo and could be used as a platform for developing novel gene-based nanomedicine approaches for corneal diseases.

Indexed as

Gene Transfer TechniquesAnimalsCells, CulturedCell SurvivalCorneaDNAFemaleGenetic VectorsHumansMiceMice, Inbred C57BLNanoparticlesOptical ImagingParticle SizePolyethyleneimineDNAPolyethyleneiminecorneafibroblastgene deliverylinear PEI nanoparticlesN:P ratio

Identifiers

PMID30699061
PMCPMC6354610
OpenAlexW2911620218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.